DSpace university logo mark
詳細検索
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 030 医学部 > 030 学術雑誌論文 >

Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study


ファイル 記述 サイズフォーマット
EJSO42_184.pdf310.83 kBAdobe PDF本文ファイル

タイトル: Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study
著者: Takatsuki, Mitsuhisa / Tokunaga, Shoji / Uchida, Shinji / Sakoda, Masahiko / Shirabe, Ken / Beppu, Toru / Emi, Yasunori / Oki, Eiji / Ueno, Shinichi / Eguchi, Susumu / Akagi, Yoshito / Ogata, Yutaka / Baba, Hideo / Natsugoe, Shoji / Maehara, Yoshihiko
発行日: 2016年 2月
出版者: Elsevier Ltd.
引用: European Journal of Surgical Oncology, 42(2), pp.184-189; 2016
抄録: Background/Aim: The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. Methods: Between May 2008 and April 2010, 40 patients were registered in a multicenter phase 2 trial of neoadjuvant chemotherapy (KSCC 0802). In Study 1, 5 independent liver surgeons from five different KSCC centers evaluated the resectability of liver metastases of colorectal cancer based on imaging studies performed before and after chemotherapy. Each surgeon was blinded to the other surgeons' evaluations. In addition, no information about the patients' characteristics was provided. In Study 2, 3 surgeons evaluated the resectability of these lesions based on imaging studies with discussion with each other, with the surgeons being provided with information on the patients' characteristics. Results: In Study 1, 13 patients (36.1%) were evaluated to be resectable at baseline, whereas 17 patients (47.2%) were evaluated to be resectable after chemotherapy. In Study 2, 4 patients (11.1%) were evaluated to be resectable at baseline, compared to 23 patients (63.9%) after chemotherapy. Conclusion: Neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab was confirmed to increase the resectability of non-resectable liver metastases of colorectal cancer according to the independent assessments of surgeons.
キーワード: Liver metastasis / Colorectal cancer / Liver resection / mFOLFOX6 / Bevacizumab / Conversion / Neoadjuvant chemotherapy
URI: http://hdl.handle.net/10069/36968
ISSN: 07487983
DOI: 10.1016/j.ejso.2015.11.007
権利: © 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
資料タイプ: Journal Article
原稿種類: author
出現コレクション:030 学術雑誌論文

引用URI : http://hdl.handle.net/10069/36968

このリポジトリに保管されている文献はすべて著作権により保護されています。
印刷やダウンロード等データの複製は、調査研究・教育または学習を目的とする場合に限定されます。

 

Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace